Delivery Order SPE2DB20D2104-SPE2DB25FMXNE
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,701.76 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL vials (10 mL) on August 14, 2025, with an ultimate completion date of August 15, 2025. This firm fixed-price delivery order carries no set-aside designation, indicating it was competitively awarded. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $2,592.90 for NovoLog 100 Unit/mL vials (10 mL) on July 28, 2025, with completion scheduled for July 29, 2025. This firm fixed price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million and extending through December 2026. The product will be delivered to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,749.33 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL vials (10 mL) on July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed price delivery order was competitively awarded without set-aside provisions. The contract calls for performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order is a child contract under...
- The Defense Logistics Agency awarded a $6,102.42 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) on July 30, 2025, with a completion date of July 31, 2025. This is a firm fixed price, non-set-aside contract to be performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL) with a ceiling value of $1,450.65. This is a firm fixed price delivery order with an ultimate completion date of August 4, 2025, and represents a competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, and involves the delivery of insulin...
- The Defense Logistics Agency awarded a $2,045.20 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of NovoLog 100 Unit/mL vials (10mL) to be delivered by July 29, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating open competitive procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL) at a ceiling value of $11,722.08. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively procured. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 8, 2025. This delivery order is a...
- The Defense Logistics Agency awarded a delivery order valued at $3,076.79 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL). This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be performed at the contractor's Conshohocken, Pennsylvania facility, with an ultimate completion date of July 31, 2025. No...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $2,108.70. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $1,803.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10 mL), an insulin medication used in diabetes management. The contract was awarded on August 1, 2025, with an ultimate completion date of August 4, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and is a child...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMXNEDelivery Order
The Defense Logistics Agency awarded a $1,275.43 delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL), an insulin product used in diabetes management. This firm fixed-price delivery order, with an ultimate completion date of August 13, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside designation, and performance will occur at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's comprehensive pharmaceutical prime vendor contract with the Defense Logistics Agency, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen supplies critical medical commodities to support military healthcare systems, the Defense Health Agency, and other federal medical programs. The company's federal contract portfolio demonstrates extensive experience fulfilling competitively awarded pharmaceutical procurement requirements across multiple therapeutic domains, positioning it as a key vendor for federal medical supply needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 8/12/25 |